Table 4.

Overview on clinical studies using future antiviral drugs and combinations

Substances (study)	RBV	Genotype	Population	Duration (wk)	Phase	Results (SVR)
SOF + GS-5816 (NS5A)[47]	±	1	TN, NCi	8	II	81% - R; 90% + R; (n = 60)
	±	2	TN, NCi	8	II	88% - R; 88% + R; (n = 52)
	±	3	TN, NCi	8	II	96% - R; 100% + R; (n = 53)
	±	1	TE, Ci, NCi	12	II	NCi: 100% (n = 38); Ci: 100% - R, 90% + R (n = 17)
	±	3	TE, Ci, NCi	12	II	NCi: 100% (n = 53); Ci: 88% - R, 96% + R (n = 52)
SOF + ACH-3102 (NS5A) (PROXY)[48]	-	1	TN, NCi	6 and 8	II	100% after 6 wk (n = 12) or 8 wk (n = 12)
SOF/LDV + Vedroprevir (SYNERGY)[49]	-	1	TN, NCi	6	II	95% (n = 20)
SOF/LDV + GS 9669 (non-NUC-NS5B) (SYNERGY)[49]	-	1	TN, NCi	6	II	95% (n = 20)
SOF + Grazoprevir + Elbasvir (C-SWIFT)[46]	-	1, 3	TN, NCi	4 or 6 (GT1)	II	SVR8: GT1: 39% after 4 wk (n = 31); 87% after 6 wk (n = 30)
				8 or 12 (GT3)		GT3: 100% after 8 and 12 wk (n = 15/14)
			TN, Ci	6 or 8 (GT1)	II	SVR8: GT1: 80% after 6 wk (n = 20); 89% after 8 wk (n = 21)
				12 (GT3)		GT3: 90% (n = 12)
Grazoprevir + Elbasvir	±	1	TN, NCi	8 or 12	II	8 wk GT1a: 80%
(C-WORTHY)[50]						12 wk: 98% - R; 93% + R
			TN, Ci	12 or 18	II	12 wk: 97% - R; 90% + R
						18 wk: 94% - R; 97% + R
			TE, Ci, NCi	12 or 18	II	12 wk: 91% - R; 94% + R
						18 wk: 97% - R; 100% + R
SMV + Samatasvir (HELIX-1)[51]	+	1b, 4	TN, NCi	12	II	SVR4: GT1b: 80% (n = 84)
						GT4: 100% (n = 9)
Asunaprevir + DCV + Beclabuvir (UNITY 1)[52]	-	1	TN, TE, NCi	12	III	TN: 91%; TE: 89%
Asunaprevir + DCV + Beclabuvir (UNITY 2)[53]	±	1	TN, TE, Ci	12	III	90% - R; 96% + R

TN: Therapy-naive; TE: Therapy-experienced; Ci: Cirrhosis; NCi: No cirrhosis; GT: Hepatitis C virus-genotype; SOF: Sofosbuvir; LDV: Ledipasvir; R: Ribavirin; SVR: Sustained virological response; SMV: Simeprevir; DCV: Daclatasvir.